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Abstract
The aim of this study was to deeper investigate the mechanisms through which ENPP1, a negative modulator of insulin
receptor (IR) activation, plays a role on insulin signaling, insulin secretion and eventually glucose metabolism. ENPP1 cDNA
(carrying either K121 or Q121 variant) was transfected in HepG2 liver-, L6 skeletal muscle- and INS1E beta-cells. Insulin-
induced IR-autophosphorylation (HepG2, L6, INS1E), Akt-Ser
473, ERK1/2-Thr
202/Tyr
204 and GSK3-beta Ser
9 phosphorylation
(HepG2, L6), PEPCK mRNA levels (HepG2) and 2-deoxy-D-glucose uptake (L6) was studied. GLUT 4 mRNA (L6), insulin
secretion and caspase-3 activation (INS1E) were also investigated. Insulin-induced IR-autophosphorylation was decreased in
HepG2-K, L6-K, INS1E-K (20%, 52% and 11% reduction vs. untransfected cells) and twice as much in HepG2-Q, L6-Q, INS1E-Q
(44%, 92% and 30%). Similar data were obtained with Akt-Ser
473, ERK1/2-Thr
202/Tyr
204 and GSK3-beta Ser
9 in HepG2 and L6.
Insulin-induced reduction of PEPCK mRNA was progressively lower in untransfected, HepG2-K and HepG2-Q cells (65%, 54%,
23%). Insulin-induced glucose uptake in untransfected L6 (60% increase over basal), was totally abolished in L6-K and L6-Q
cells. GLUT 4 mRNA was slightly reduced in L6-K and twice as much in L6-Q (13% and 25% reduction vs. untransfected cells).
Glucose-induced insulin secretion was 60% reduced in INS1E-K and almost abolished in INS1E-Q. Serum deficiency activated
caspase-3 by two, three and four folds in untransfected INS1E, INS1E-K and INS1E-Q. Glyburide-induced insulin secretion was
reduced by 50% in isolated human islets from homozygous QQ donors as compared to those from KK and KQ individuals.
Our data clearly indicate that ENPP1, especially when the Q121 variant is operating, affects insulin signaling and glucose
metabolism in skeletal muscle- and liver-cells and both function and survival of insulin secreting beta-cells, thus
representing a strong pathogenic factor predisposing to insulin resistance, defective insulin secretion and glucose
metabolism abnormalities.
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Introduction
Type 2 diabetes mellitus is a complex disorders due to the
combination of genetic and environmental factors. Impaired
insulin action (i.e. insulin resistance) in liver and skeletal muscle as
well as reduced pancreatic beta-cell insulin secretion are
pathogenic for type 2 diabetes [1]. In the presence of insulin
resistance, glucose homeostasis is preserved by compensatory
hyperinsulinemia [2,3], with type 2 diabetes ensuing only when
beta-cells fail to secrete sufficient insulin to adequately counteract
impaired insulin sensitivity. Besides the established role of
abnormal insulin signaling in predisposing to insulin resistance
[4], studies in animal models have proposed that insulin signaling
is essential also for beta-cell insulin secretion [5,6,7,8]. Along the
same line of evidences, human non synonymous genetic
variations which affect the insulin signaling pathway [9,10,
11,12] and which have been associated with in vivo insulin
resistance [13,14], are also able to affect insulin secretion in vivo
[13,15], in isolated human islets [8,16,17] and in cultured beta-
cells [8,18]. Thus, an intriguing scenario has emerged suggesting
that abnormalities impairing insulin signaling play a role on
glucose homeostasis not only by affecting glucose metabolism in
liver and skeletal muscle, but also by inducing defective insulin
secretion [19,20].
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is a class II transmembrane glycoprotein, which inhibits insulin
receptor (IR) signaling and which has been, therefore, proposed as
a candidate for insulin resistance [20,21]. In fact, in both cultured
cells [22,23,24,25,26,27] and mice [28,29], increasing ENPP1
expression causes impaired insulin signaling and action. Moreover,
ENPP1 is overexpressed in skeletal muscle, adipose tissue,
fibroblasts and lymphocytes of insulin-resistant individuals
[21,30,31,32,33]. Further support to the notion that ENPP1
may play a role on human insulin resistance derives from studies
on the ENPP1 K121Q polymorphism [34], which has drawn some
attention as a genetic determinant of human insulin resistance.
Indeed, the Q121 variant has been associated with insulin
resistance in several [35,36,37] although not all [38] large studies.
Interestingly, it also predicts incident major cardiovascular events
[39], an important clinical outcome of insulin resistance. These
epidemiological associations have been proposed to be mediated
by a stronger inhibitory activity on IR signaling, as compared to
that exerted by the K121 variant [25,34,40]. However, such
functional studies pointing to the K121Q polymorphism as a gain
of function aminoacid substitution, have been obtained in non
typical insulin target cells [25,34,40] and may not, therefore, be
considered as conclusive. More recently, a deleterious effect of the
Q121 variant on in vivo insulin secretion has been reported [37].
Whether this is given by a direct detrimental effect on beta-cells or,
in contrast, it is secondary to alterations of the metabolic milieu
related to whole body insulin resistance, is an additional open
question, which deserves further studies to be answered.
The aim of this study was to deeper investigate in vitro the
mechanisms through which ENPP1 plays a role on insulin
signaling, insulin secretion and eventually glucose metabolism.
To this purpose, the effect of ENPP1 expression (either the K121
or the Q121 variant) was investigated in the three most important
cell types for maintenance of glucose homeostasis (i.e. liver-,
skeletal muscle- and pancreatic beta-cells). In details, we studied i)
insulin-induced IR activation in all three cell types, ii) downstream
insulin signaling and subsequent insulin action on glucose
metabolism in liver- and skeletal muscle-cells and iii) beta-cells
insulin secretion and survival. The data we obtained clearly
indicate that ENPP1, especially when the Q121 variant is
operating, exerts a direct deleterious effect on all these cell types,
thus representing a strong candidate as a pathogenic factor
predisposing to insulin resistance, defective beta-cell insulin
secretion and glucose metabolism abnormalities.
Results
Studies on IR autophosphorylation
IR tyrosine autophosphorylation was studied in human liver
HepG2 cells, rat skeletal muscle L6 cells and rat pancreatic INS1E
beta-cells. To this purpose, cells were transfected with either
ENPP1-K121 (HepG2-K, L6-K and INS1E-K) or ENPP1-Q121
(HepG2-Q, L6-Q, and INS1E-Q) cDNA, and then stimulated
with insulin as described in methods. Immunoblot analysis showed
that insulin stimulation induced autophosphorylation of IR-beta
subunit in HepG2 (Figure 1 A), L6 (Figure 1 B) and INS1E-neo
(Figure 1 C) control cells. This effect was variably reduced in
HepG2-K (20% reduction; Figure 1 A), L6-K (52% reduction;
Figure 1 B) and INS1E-K (11% reduction; Figure 1 C). Such
reduction was approximately doubled in HepG2-Q (44%
reduction; Figure 1 A), L6-Q (92% reduction; Figure 1 B) and
INS1E-Q cells (30% reduction; Figure 1 C).
These data, strongly suggest that ENPP1 is an inhibitor of IR
autophosphorylation in typical insulin target cells, as well as in
Figure 1. Studies on IR autophosphorylation in HepG2 (A), L6
(B) and INS1E (C) cells. Cells were either transfected, or not, with
ENPP1-K121 cDNA or with ENPP1-Q121 cDNA and then stimulated with
insulin as described in methods. Equal amount of protein from cell
lysates was immunoprecipitated with anti-PY antibody, separated by
SDS-PAGE and probed with IR-beta subunit antibody. Bars (upper
panels) represent quantitative analysis of IR autophosphorylation
calculated as percentage of that of stimulated untransfected cells in
each experiment (mean 6 SEM), while representative immunoblots
from the same experiment are shown in lower panels. (A) In HepG2
cells, insulin induced IR-beta subunit autophosphorylation. This effect
was significantly reduced in HepG2-K (*p=0.02, fourth vs. second bar,
n=3 experiments in separate times) and more profoundly in HepG2-Q
(
1p,0.001, sixth vs. second bar, n=3 experiments in separate times)
cells. When properly tested, a progressive reduction was observed from
control to HepG2-K and then HepG2-Q cells (p for trend,0.001). (B) In
L6 cells, insulin induced IR-beta autophosphorylation. As compared to
control cells, insulin effect was significantly reduced in L6-K (*p=0.01,
fourth vs. second bar, n=3 experiments in separate times) and more
profoundly in L6-Q cells (
1p,0.001, sixth vs. second bar, n=3
experiments in separate times). When properly tested, a progressive
reduction was observed from control to L6-K and then L6-Q cells (p for
trend,0.001). (C) In INS1E cells, insulin induced IR-beta autopho-
sphorylation. As compared to control cells, insulin effect was only
slightly and not significantly reduced in INS1E-K (fourth vs. second bar,
n=3 experiments in separate times) and significantly reduced in INS1E-
Q cells (30% reduction *p=0.02, sixth vs. second bar, n=3 experiments
in separate times). When properly tested, a progressive reduction was
observed from INS1E-neo to INS1E-K and then INS1E-Q cells (p for
trend=0.024).
doi:10.1371/journal.pone.0019462.g001
Role of ENNP1 on Insulin Action and Secretion
PLoS ONE | www.plosone.org 2 May 2011 | Volume 6 | Issue 5 | e19462insulin secreting beta-cells and that the Q121 variant is a gain of
function aminoacid substitution with increased inhibitory activity.
Studies in non insulin target cells have suggested that ENPP1
inhibitory activity on IR autophosphorylation is mediated by
ENPP1/IR interaction [24,25]. Given our present data, we
sought to replicate this finding also in typical insulin target cells,
as is the case of HepG2. Upon insulin stimulation, as compared
to control cells, the amount of ENPP1 associated with IR
(Figure 2) was increased by 54 fold in HepG2-K and by 97 fold
HepG2-Q cells. This confirms that also in liver cells ENPP1
inhibitory function on IR autophosphorylation is paralleled by
ENPP1/IR interaction.
Studies on insulin signaling in HepG2 and L6 cells
In order to characterize the effect of ENPP1 on downstream
insulin signaling in typical insulin target cells, we investigated Akt-
Ser
473, GSK3-beta Ser
9 and ERK1/2 Thr
202/Tyr
204 insulin-
induced phosphorylation in HepG2 and L6 cells (Supporting
Information S1). Briefly, transfection of ENPP1-K121 cDNA in
both HepG2 and L6 cells was able to significantly reduce insulin-
induced Akt-Ser
473, GSK3-beta Ser
9 and ERK1/2 Thr
202/Tyr
204
phosphorylation (Figures S2, S3, S4). In cells transfected with
ENPP1-Q121 cDNA, this inhibitory effect was magnified in most
of these steps (Supporting Information S1 and Figures S2, S3, S4).
The general picture that can be drawn from these data strongly
suggests that the greater inhibitory effect on IR autophosphoryla-
tion exerted by the Q121 variant is retained at most downstream
post receptor steps, thus resulting in a more profound inhibition of
the entire insulin signaling pathway in both cell types.
Studies on insulin action in HepG2 and L6 cells
Insulin action on glucose metabolism was then assessed by
studying mRNA level of the gluconeogenetic enzyme PEPCK in
HepG2 cells and by investigating glucose transport and GLUT 4
expression level in L6 cells. PEPCK mRNA level was reduced by
65% upon insulin stimulation in untransfected HepG2 control
cells. This reduction was progressively smaller in HepG2-K (54%
reduction, p=0.05 vs. reduction in control cells, n=3) and in
HepG2-Q cells (23% reduction, p=0.009 vs. reduction in control
cells, n=3). Insulin stimulation induced a 60% increase of glucose
uptake in untransfected L6 control cells. In contrast, insulin effect
on glucose transport was totally abolished in L6-K (n=3) and L6-
Q cells (n=3). Of note, as compared to control cells, GLUT 4
mRNA level was slightly and not significantly reduced in L6-K
(13% reduction, p=0.22, n=3) and significantly decreased in L6-
Q cells (25% reduction, p=0.01, n=3). Similarly, when GLUT 1
mRNA level was measured, no difference at all was observed in
L6-K (n=3), while a significant reduction was observed in L6-Q
(26% reduction, p=0.03, n=3) as compared to control cells.
Studies on beta-cell insulin secretion and survival
Increasing glucose concentration significantly stimulated insulin
secretion in INS1E-neo control cells (Figure 3 A). This effect was
markedly reduced in INS1E-K cells (60% reduction, Figure 3 A)
and almost abolished in INS1E-Q cells (Figure 3 A). Glyburide
significantly stimulated insulin secretion in INS1E-neo control cells
(Figure 3 B); this effect was almost completely abolished in INS1E-
K with no further effect observed in INS1E-Q cells (Figure 3 B).
We then tested the role of ENPP1 on INS1E beta-cell survival.
Serum deficiency in INS1E-neo control cells induced a 2 fold
increase of caspase-3 activation (Figure 4). This activation was
exacerbated in INS1E-K cells (4.6 fold increase n=4), and even
more profoundly in INS1E-Q (5.9 fold increase, n=4). The
overall picture, that can be drawn by these findings, is that
increasing ENPP1 expression in cultured beta-cells induces
defective insulin secretion and increased apoptosis and that, also
in this context, the Q121 variant is a gain of function aminoacid
substitution. Based on our previous observation suggesting that
homozygote individuals for the Q121 variant (i.e. QQ subjects)
have defective insulin secretion [37], we sought to test the direct
effect of this variant in the homozygote state also in isolated
human islets from 85 donors. As shown in Figure 5, islets from the
only two QQ donors, we had the chance to work with, tended to
secrete approximately 50% less insulin under both glucose and
glyburide stimulation.
Discussion
An important finding of this study is that increasing ENPP1
expression in liver HepG2 and skeletal muscle L6 cells affects IR
activation, downstream insulin signaling and insulin action on
glucose metabolism. In both cell types, the relatively rare ENPP1
Q121 variant exhibits, as compared to the K121 variant, a greater
inhibition of IR activation and of most subsequent insulin signaling
and action steps, thus behaving as a gain of function aminoacid
substitution. In HepG2 cells, the Q121 variant shows a stronger
physical interaction with the IR. This strengthen the hypothesis
emerged from previous studies carried out in non typical insulin
target cells that, as compared to ENPP1 K121, the Q121 variant is
a stronger inhibitor of insulin signaling and action because of a
stronger protein-protein interaction with the IR [25].
An additional finding of this study, which is entirely novel, is
that ENPP1 expression induces defective IR activation, reduced
insulin secretion upon stimulation of both glucose and glyburide,
Figure 2. ENPP1/IR interaction. Lower panel: HepG2 cells were
either transfected (lanes 2–3) or not (lane 1) with ENPP1-K121 cDNA
(lane 2) or with ENPP1-Q121 cDNA (lane 3) and stimulated with insulin
as described in methods. Total cell lysates were immunoprecipitated by
using anti IR-alpha subunit antibody and ENPP1/IR interaction was
evaluated by Western blot analysis with anti-ENPP1 specific antibody.
Bars (upper panel) represent quantitative analysis of three independent
Western blots (mean 6 SEM), while a representative experiment is
shown in the lower panel. As compared to HepG2 control cells, the
amount of ENPP1 associated with IR was greatly increased in HepG2-K
(*p=0.002, second vs. first bars, n=3 experiments in separate times)
and even more profoundly in HepG2-Q (
1p,0.001, third vs. first bars,
n=3 experiments in separate times) cells. When properly tested, a
progressive increase of ENPP1/IR interaction was observed from control
to HepG2-K and then HepG2-Q cells (p for trend,0.001).
doi:10.1371/journal.pone.0019462.g002
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also in most of these circumstances, the Q121 variant behaves as a
gain of function aminoacid substitution. Although not conclusive
because too sparse, also data in isolated human islets are in line
with an inhibitory effect of the Q121 variant on insulin secretion,
at least when present in the homozygous state.
Taken altogether, these findings clearly indicate that ENPP1,
especially when the Q121 variant is operating, affects in vitro the
most important tissues controlling glucose metabolism, including
liver, skeletal muscle and insulin secreting beta-cells. A deleterious
effect of ENPP1 on IR signaling and insulin action has been
recently reported also in rat 3T3L-1 adipocytes [26], thus
providing evidences for a role of ENPP1 in another very important
insulin target tissue. These data in insulin target cells are fully
compatible with those obtained in genetically modified animals in
which changes in ENPP1 expression was directly correlated with
deterioration of insulin sensitivity and abnormal glucose homeo-
stasis [28,29,41].
As far as data on glucose- as well as glyburide-stimulated insulin
secretion is concerned, our findings contribute to support an
emerging scenario suggesting that IR signaling abnormalities have
a direct, detrimental role on insulin secreting beta-cells [5,6,7,19].
Figure 3. Studies on glucose-induced (A) and glyburide-induced (B) insulin secretion in INS1E cells. As compared to that of INS1E-neo
control cells, glucose-induced insulin secretion (A) was markedly reduced in INS1E-K cells (p,0.005, n=5 experiments in separate times) and almost
completely abolished in INS1E-Q cells (p,0.0001, n=5 experiments in separate times). Data are expressed as percentage of maximal secretion
showed in INS1E-neo cells (mean 6 SEM), which for glucose stimulation is obtained at 16.6 mM. When properly tested, a progressive reduction was
observed from INS1E-neo to INS1E-K and then INS1E-Q cells (p for trend,0.001). As compared to that of INS1E-neo control cells, glyburide-induced
insulin secretion (B) was almost completely abolished in both in INS1E-K and INS1E-Q cells (*p,0.0001 for both, n=3 experiments in separate times).
Data are expressed as percentage of glyburide-induced insulin secretion in INS1E-neo cells (mean 6 SEM).
doi:10.1371/journal.pone.0019462.g003
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reporting that other naturally occurring amino acid substitutions
affecting insulin signaling, including IRS1 G972R [15,17] and
TRIB3 Q84R, directly affects insulin secreting beta-cells [8,16].
The mechanism through which ENPP1 affects insulin secretion
has not been addressed in this study. In beta-cells it has been
reported that insulin signaling, through the activation of IRS1,
PI3K [5,42] and Akt-2 [43], increases Ca
++ influx, especially from
the endoplasmic reticulum and, therefore, facilitates insulin-
containing granules trafficking and exocytosis. So, although
entirely speculative, it can be hypothesized that, in cells over-
expressing ENPP1, reduced insulin signaling causes defective
intracellular Ca
++ availability and eventually reduced glucose- as
well as glyburide-stimulated insulin secretion.
As far as our present data on the Q121 variant is concerned, it is
of note they are quite consistent with previous findings obtained in
vivo. As a matter of fact, several [35,36,37] although not all [38]
large studies have reported that individuals carrying the Q121
variant are insulin resistant as compared to KK subjects and that
those carrying the QQ genotype also show defective insulin
secretion [37]. Despite so many in vitro and in vivo findings
coherently reported by several groups, the most updated meta-
analysis, involving a huge number of individuals shows that a
perfect proxy of the ENPP1 Q121 variant is not an established (i.e.
at genome-wide level of statistical significance) marker of type 2
diabetes [44]. Several factors, intrinsic to study designs and data
analyses of most GWAS (recently reviewed in [20]),might explain,
at least partly, this apparent discrepancy. Nonetheless, the lack of
established association with type 2 diabetes leaves uncertain the
role of the Q121 variant on glucose homeostasis.
In conclusion, the data we obtained, clearly indicate that
ENPP1 exerts in vitro a direct detrimental effect on the most
important tissues for insulin sensitivity, insulin secretion and,
eventually, glucose metabolism. Additional attempts, aimed at
better clarify the role of ENPP1 as a pathogenic factor
predisposing to insulin resistance-related abnormalities and type
2 diabetes, are definitively needed.
Materials and Methods
Cell Lines
HepG2 cells (ATCC, Manassas, USA) were maintained at 37uC
and 5% CO2 in DMEM/F12 containing 10% FBS. L6 (ATCC,
Manassas, USA) were maintained in DMEM containing 25 mM
glucose with 10% FBS. Rat insulin-secreting INS1E cells (a kind
gift from C. B. Wollheim, Department of Cell Physiology and
Metabolism, University of Geneva, Geneva, Switzerland) were
grown at 37uC and 5% CO2, in RPMI 1640 medium containing
2 mM L-glutamine supplemented with 10% heat-inactivated FBS.
Plasmid
Full-length cDNA of ENPP1-K121 was kindly provided by Dr.
I.D. Goldfine (San Francisco, University of California, USA) and
Figure 4. Apoptosis in INS1E cells. Apoptosis in INS1E was assessed
by determining cleaved caspase-3 expression by Western blot. Equal
amount of protein from cell lysates was separated by SDS-PAGE and
probed with specific antibody. Bars (upper panel) represent quantita-
tive analysis of cleaved caspase-3 calculated as percentage of that of
non serum deficient control cells for each experiment (mean 6 SEM),
while representative immunoblot from the same experiment is shown
in lower panel. A significant increment in cleaved caspase-3 expression
was observed in INS1E-Q cells as compared to INS1E-neo control cells
(*p,0.05, n=4 experiments in separate times). When properly tested, a
progressive increase was observed from INS1E-neo to INS1E-K and then
INS1E-Q cells (p for trend=0.038).
doi:10.1371/journal.pone.0019462.g004
Figure 5. Insulin secretion in isolated human islets from 85
donors. Insulin secretion stimulated by glucose (16.7 mM, (A)) or
glyburide (100 mM, (B)) was measured on isolated human islets as
described in methods. Islets from QQ donors (n=2) tended to secrete
less insulin than islets from KK (n=59) and KQ (n=24) individuals under
both conditions. Data (mean 6 SEM) are expressed as stimulation index
calculated by dividing stimulated insulin release (either by glucose
16.7 mM (A) or by glyburide 100 mM( B)) over basal insulin release (at
glucose 3.3 mM).
doi:10.1371/journal.pone.0019462.g005
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directed mutagenesis as previously described [45]. Both cDNAs
were cloned in mammalian expression vector pRK7.
Transfections
HepG2 and L6 cells were transiently transfected with the full
length cDNA of either ENPP1-K121 (HepG2-K and L6-K,
respectively) or ENPP1-Q121 (HepG2-Q and L6-Q, respectively)
by using TransIT reagent according to the manufacturers’
instruction (Mirus), and then starved overnight in DMEM
containing either 0.5% FBS or 0.25% BSA before experiments.
ENPP1 protein expression in each condition was evaluated by
Western blot analysis (Figure S1 A and S1 B). INS1E cells were
either transfected with a plasmid (pRK7-neo) containing the
neomycin resistance gene (INS1E-neo), or with the pRK7-neo plus
the ENPP1-K121 cDNA (INS1E-K) or with the pRK7-neo plus
ENPP1-Q121 cDNA (INS1E-Q) by using the Fugene Transfection
Reagent (Roche, Germany) according to the company’s instruc-
tions. Clones expressing a similar amount of ENPP1 were selected
(Figure S1 C).
Western blot
Cells lysates were separated by SDS-PAGE and transferred to
nitrocellulose membrane (Amersham Pharmacia Biotech). Blots
were probed with specific antibodies HRP-conjugated anti-goat,
anti-mouse and anti-rabbit antibodies (Santa Cruz Biotechnology)
and the chemiluminescent substrate (Super Signaling West Pico
Thermo Scientific, Pierce or ECL by Amersham, GE Healthcare)
was used for detection. Gel images were acquired by using
Molecular Imager ChemiDoc XRS (Biorad) and analyzed by
using Kodak Molecular Imaging Software 4.0 or IMAGEJ 1.40 g
(Wayne Rasband, NIH).
IR phosphorylation
HepG2, HepG2-K, HepG2-Q cells, L6, L6-K and L6-Q cells
and INS1E-neo, INS1E-K and INS1E-Q cells were stimulated
with 10
26 M insulin for 5 minutes at 37uC. Following cell lysis
equal amount of protein was immunoprecipitated with anti-PY
antibody (4G10 Platinum, Millipore, Italy), and analyzed by
Western blot with anti IR-beta subunit antibody (C19, Santa Cruz
Biotechnology, CA). IR phosphorylation was calculated as
percentage of stimulated untransfected cells and expressed as
means 6 SEM.
ENPP1/IR interaction
Following insulin stimulation (10
26 M for 5 minutes) and cell
lysis, 2 mg of proteins were immunoprecipitated with anti IR
alpha-subunit antibody and analyzed by Western blot analysis by
using ENPP1 specific polyclonal antibody (N20 Santa Cruz
Biotechnology, CA). Data were calculated as percentage of
stimulated untransfected cells and expressed as mean 6 SEM.
Insulin downstream signaling
Following insulin stimulation (10
26 M for 5–10 minutes) and
cell lysis, equal amount of protein was analyzed by western blot




204, phospho-GSK3 beta Ser
9 (Cell
Signaling, Boston, MA). The blot were then stripped and re-
probed with antibodies against Akt, ERK1/2 and GSK3 beta for
normalization (Cell Signaling, Boston, MA). Data were calculated
as percentage of stimulated untransfected cells and expressed as
means 6 SEM.
PEPCK mRNA level
Thirty hours after transfection HepG2, HepG2-K and HepG2-
Q cells were starved for 18 hours and then stimulated with
10
26 M insulin for 10 hours. Total RNA extraction and cDNA
synthesis were performed as previously described [45]. PEPCK
mRNA level was measured by RT-PCR by using the following
primers: 59-ATGTATGTCATCCCATTCAGC- 39 and 59-
AATGTCATCACCCACACATTC-39 [46]. Data were calculat-
ed as percentage of unstimulated untransfected HepG2 cells and
expressed as means 6 SEM.
2-Deoxy-D-glucose uptake in L6
2-Deoxy-D-glucose uptake in L6, L6-K and L6-Q cells was
measured as previously reported [47]. Data were calculated as
percentage over unstimulated cells and expressed as means 6
SEM.
GLUT 4 and GLUT 1 mRNA level
Total RNA from L6, L6-K and L-6Q cells was extracted and
cDNA was obtained as previously described [45]. GLUT 4 and
GLUT 1 mRNA level was measured by RT-PCR by using the
following primers: 59-CAGAAGGTGATTGAACAGAG-39,5 9-
AATGATGCCAATGAGAAAGG-39 and 59-CAGCCGATGT-
GACCCGAGAC-39,5 9-GACGATACCCGAGCCGATGG-39
respectively [48]. Data were calculated as percentage of untrans-
fected L6 cells and expressed as means 6 SEM.
Insulin secretion in INS1E cells
Insulin secretion was evaluated as previously described [49].
Briefly, INS1E-neo, INS1E-K and INS1E-Q cells were seeded in
six-well plates at a density of 8610
5 cells/well and, after 24 hours,
the medium was removed and cells washed twice with glucose-free
Krebs solution (pH 7.4). After a 60 minute preincubation period
(37uC, 5% CO2) in Krebs solution containing 2.7 mM glucose,
insulin secretion was determined in presence of increasing glucose
concentrations (2.7; 5.5; 11.1; 16.6 and 22.2 mM) or 100 mM
glyburide, a concentration used in previous in vitro studies [50].
After 60 minutes at 37uC, 5% CO2, aliquots of surnatant were
taken for the measurement of insulin secretion (Rat/Mouse Insulin
ELISA Kit, Billerica, MA, U.S.A.), while total protein content was
determined using BCA protein Assay (Thermo scientific, Rock-
ford, USA). Data were expressed as percentage of maximal
secretion showed in INS1E-neo cells, which for glucose stimulation
was obtained at 16.6 mM.
Apoptosis assay
For caspase-3 experiments, INS1E-neo, INS1E-K and INS1E-
Q cells were cultured in RPMI or starved overnight in serum-free
RPMI containing 1.1 mM glucose and 0.1% BSA. After cells lysis,
equal amount of protein was analyzed by Western blot, using
cleaved caspase 3 (asp 175) antibody (Cell Signaling, Boston, MA,
USA). Data were calculated as percentage of untreated INS1E-neo
cells (% of basal) and expressed as means 6 SEM.
Pancreas donors
Pancreata were collected from 85 non diabetic brain-dead
multiorgan donors (58616 years 49.4% females) after informed
consent was obtained in writing from family members, as
previously reported [51]. The islet isolation centre has permission
to prepare isolated islets and to use them for scientific research if
they are not suitable for clinical islet transplantation, in
accordance with national laws and our institutional ethical rules
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Human islet preparation
Pancreatic islets were prepared by collagenase digestion and
density gradient purification, as previously reported in detail. After
isolation, islets were cultured in M-199 culture medium as
previously described [52].
DNA extraction
DNA was extracted from batches of 2000 isolated islets in
according to the Wizard genomic DNA purification protocol
(Promega, Madison, WI, USA). Total DNA was quantified by
absorbance at A260/A280 nm (ratio.1.65) in a Perkin-Elmer
spectrophotometer, and its integrity assessed by electrophoresis on
1.0% agarose gel by ethidium bromide staining.
Insulin secretion in isolated human islets
Insulin secretion was determined as previously described [52].
Briefly, following a 45 minute preincubation period at 3.3 mM
glucose, batches of 15 islets of comparable size were kept at 37uC
for 45 minutes in Krebs-Ringer bicarbonate solution (KRB) and
0.5% albumin, pH 7.4, containing 3.3 mM glucose. At the end of
this period, the medium was completely removed and replaced
with KRB containing 16.7 mM glucose and 3.3 mM G plus
100 mM glyburide [53,54]. After an additional 45 minute of
incubation, the medium was removed and stored at 220uC until
insulin concentrations were measured by immunoradiometric
assay (Pantec Forniture Biomediche, Turin, Italy). Data are
expressed as stimulation index calculated by dividing stimulated
insulin release (either by glucose 16.7 mM or by glyburide
100 mM) over basal insulin release (at glucose 3.3 mM).
Genotyping of isolated human islets
Polymorphism K121Q (rs1044498) at ENPP1 locus was
genotyped by TaqMan allele discrimination (assay
C_16190162_10, Applied Biosystems, Forster City, CA) on the
HT7900 platform (Applied Biosystems). The failure rate was
,1%. Genotyping quality was assessed by including positive
controls with known genotypes. The agreement rate was .99%.
Genotype distribution in the study sample was in Hardy-Weinberg
equilibrium.
Statistical analysis
Differences between mean values were evaluated by unpaired or
paired Student’s t test, as appropriate. General linear model was
used to test the hypothesis that insulin signaling, action and
secretion was progressively worse from control cells to K-cells and
then Q-cells.
Supporting Information
Figure S1 ENPP1 expression in HepG2, L6 and INS1E
cells. HepG2 and L6 cells (A, B) were transiently transfected with
the full length cDNAs of either ENPP1-K121 (HepG2-K and L6-
K, respectively) or ENPP1-Q121 (HepG2-Q and L6-Q, respec-
tively). ENPP1 protein content was then evaluated by Western blot
analysis with specific antibody. Representative experiments are
shown. INS1E cells (C) were stably transfected as described in
methods. Two cell clones were isolated after transfection with a
plasmid (pRK-7-neo) containing the neomycin resistance gene and
co-transfected with ENPP1-K121 cDNA (INS1E-K, lane 3) or with
ENPP1-Q121 cDNA (INS1E-Q, lane 4). Two clones expressing a
similar amount of ENPP1 were selected. Three different
experiments were carried out and a representative experiment is
shown.
(TIF)
Figure S2 Studies on Akt-S
473 phosphorylation in
HepG2 and L6 cells. Cells were either transfected or not with
ENPP1-K121 cDNA or with ENPP1-Q121 cDNA and stimulated
with insulin as described in methods. Equal amount of protein
from cell lysates was separated by SDS-PAGE and Akt-S
473
phosphorylation was evaluated by using specific antibody by
Western blot analysis. To evaluate Akt protein content, blots were
stripped and reprobed with specific antibody. Bars (upper panels)
represent quantitative analysis of Akt-S
473 phosphorylation
calculated in each single experiment as percentage of that of
insulin stimulated untransfected cells (mean 6 SEM), while
representative immunoblots from the same experiment are shown
in the lower panels. In HepG2 cells (A), insulin strongly stimulated
Akt-S
473 phosphorylation. As compared to control cells, insulin
effect was significantly and similarly reduced in both HepG2-K
and HepG2-Q cells (*p,0.005, both fourth and sixth vs. second
bar, n=3 experiments in separate times). In L6 cells (B), insulin
strongly induced Akt-S
473 phosphorylation. As compared to
control cells, insulin effect was significantly reduced in both L6-
K (*p=0.02, fourth vs. second bar, n=3 experiments in separate
times) and L6-Q cells (
1p,0.001, sixth vs. second bar, n=3
experiments in separate times). When properly tested, a progres-
sive reduction was observed from control to L6-K and then L6-Q
cells (p for trend,0.001).
(TIF)
Figure S3 Studies on GSK3-beta S
9 phosphorylation in
HepG2 and L6 cells. Cells were either transfected or not with
ENPP1-K121 cDNA or with ENPP1-Q121 cDNA and stimulated
with insulin as described in methods. Equal amount of protein
from cell lysates were separated by SDS-PAGE and GSK3-beta S
9
phosphorylation was evaluated by using specific antibody by
Western blot analysis. GSK3-beta protein content was evaluated
by stripping and reprobing the same blot with specific antibody.
Bars (upper panels) represent quantitative analysis of GSK3-beta
S
9 phosphorylation calculated in each single experiment as
percentage of that of insulin stimulated untransfected cells (mean
6 SEM), while representative immunoblots from the same
experiment are shown in the lower panels. In HepG2 cells (A),
insulin greatly induced GSK3-beta S
9 phosphorylation. As
compared to control cells, this effect was reduced in HepG2-K
(*p=0.02, fourth vs. second bar, n=3 experiments in separate
times) and more strongly in HepG2-Q cells (
1p,0.001, sixth vs.
second bar, n=3 experiments in separate times). When properly
tested, a progressive reduction was observed from control to
HepG2-K and then HepG2-Q cells (p for trend=0.002). In L6
cells (B), insulin induced GSK3-beta S
9 phosphorylation. As
compared to control cells, this effect was similarly reduced in L6-K
(*p=0.003, fourth vs. second bar, n=3 experiments in separate
times) and in L6-Q cells (
1p,0.001, sixth vs. second bar, n=3
experiments in separate times). When properly tested, a progres-
sive reduction was observed from control to L6-K and then L6-Q
cells (p for trend=0.003).
(TIF)
Figure S4 Studies on ERK1/2 Thr
202/Tyr
204 phosphor-
ylation in HepG2 and L6 cells. Cells were either transfected
or not with ENPP1-K121 cDNA or with ENPP1-Q121 cDNA and
stimulated with insulin as described in methods. Equal amount of
protein from cell lysates was separated by SDS-PAGE and ERK1/
2 Thr
202/Tyr
204 phosphorylation was evaluated by using specific
antibody by Western blot analysis. ERK1/2 protein content was
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antibody. Bars (upper panels) represent quantitative analysis of
ERK1/2 Thr
202/Tyr
204 phosphorylation calculated in each single
experiment as percentage of that of insulin stimulated untrans-
fected cells (mean 6 SEM), while representative immunoblots
from the same experiment are shown in the lower panels. In
HepG2 cells (A), insulin induced ERK1/2 activation. As
compared to control cells, insulin effect was significantly reduced
in both HepG2-K (*p=0.003, fourth vs. second bar, n=3
experiments in separate times) and slightly more HepG2-Q cells
(
1p,0.001, sixth vs. second bar, n=3 experiments in separate
times). When properly tested, a progressive reduction was
observed from control to HepG2-K and then HepG2-Q cells (p
for trend,0.001). In L6 cells (B), insulin induced a great ERK1/2
activation. This effect was significantly reduced in L6-K
(*p,0.001, fourth vs. second bar, n=3 experiments in separate
times) and more profoundly in L6-Q cells (*p,0.001, sixth vs.
second bar, n=3 experiments in separate times). When properly
tested, a progressive reduction was observed from control to L6-K
and then L6-Q cells (p for trend,0.001).
(TIF)
Supporting Information S1 Studies on insulin signaling in
HepG2 and L6 cells.
(DOC)
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